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Introduction: The staging system for malignant pleural mesothelioma 
is controversial. To revise this system, the International Association 
for the Study of Lung Cancer Staging Committee developed an inter-
national database. This report analyzes prognostic variables in a sur-
gical population, which are supplementary to previously published 
CORE variables (stage, histology, sex, age, and type of procedure).
Methods: Supplementary prognostic variables were studied in three 
scenarios: (1) all data available, that is, patient pathologically staged 
and other CORE variables available (2) only clinical staging avail-
able along with CORE variables, and (3) only age, sex, histology, and 
laboratory parameters are known. Survival was analyzed by Kaplan–
Meier, prognostic factors by log rank and stepwise Cox regression 
modeling after elimination of nonsignificant variables. p value less 
than 0.05 was significant.
Results: A total of 2141 patients with best tumor, node, metastasis 
(TNM) stages (pathologic with/without clinical staging) had nonmiss-
ing age, sex, histology, and type of surgical procedure. Three prognos-
tic models were defined. Scenario A (all parameters): best pathologic 
stage, histology, sex, age, type of surgery, adjuvant treatment, white 
blood cell count (WBC) (≥15.5 or not), and platelets (≥400 k or not) 
(n = 550). Scenario B (no surgical staging): clinical stage, histol-
ogy, sex, age, type of surgery, adjuvant treatment, WBC, hemoglobin 
(<14.6 or not), and platelets (n = 627). Scenario C (limited data): 
histology, sex, age, WBC, hemoglobin, and platelets (n = 906).
Conclusion: Refinement of these models could define not only the 
appropriate patient preoperatively for best outcomes after cytoreduc-
tive surgery but also stratify surgically treated patients after clinical 
and pathologic staging who do or do not receive adjuvant therapy.
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(J Thorac Oncol. 2014;9: 856–864)
The role of surgery in patients with malignant pleural meso-thelioma (MPM) would be less controversial if there was 
an accurate and minimally invasive method that could fore-
cast outcomes for individuals who are surgical candidates. 
MPM patients tend to be older individuals who are frequently 
functionally impaired and may have difficulty with aggressive 
therapy; however, there is a cadre of MPM patients who, with 
favorable biology and a multimodal approach, benefit from 
intense therapy. Factors that predict to a poor overall survival 
or rapid time to progression could potentially help medical 
oncologists and surgeons select only those patients who should 
undergo potentially harmful cytoreductions with the present 
4% operative mortality.1 The best-known clinical prognostic 
scoring systems for MPM have originated from the European 
Organisation for Research and Treatment of Cancer (EORTC) 
and the Cancer and Leukemia Group B,2,3 and use a combina-
tion of biological and clinical factors. Poor performance status 
(PS), nonepithelioid histology, male sex, low hemoglobin, high 
platelet count, high white blood cell count, and high lactate 
dehydrogenase were found to be poor prognostic indicators in 
mesothelioma, and subsequently validated. Such detailed anal-
yses with sufficient numbers of patients for meaningful assess-
ment have been lacking in the surgically treated population.
In collaboration with the International Mesothelioma 
Interest Group, the International Staging and Prognostic 
Factors Committee of the International Association for the 
Study of Lung Cancer (IASLC) formed a Mesothelioma 
Domain to improve the current staging system resulting in the 
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first large, international MPM database, which includes more 
than 2000 staged patients with MPM diagnosed from 1995 to 
2008 (see Supplementary Appendices, Supplementary Digital 
Content, http://links.lww.com/JTO/A583). As described by 
Rusch et al.,4 a set of covariates were identified as predic-
tive of survival in a “CORE” model for this analysis, which 
included best staging information, age, sex, histology (epithe-
lioid or not), and type of surgical procedure (palliative versus 
extrapleural pneumonectomy or pleurectomy decortication. 
This report summarizes an analysis of additional tumor or 
patient characteristics for their prognostic ability as mandated 
by the Prognostic Factors Subcommittee of the Mesothelioma 
Domain. Armed with the CORE model described above, the 
aim of this study was to analyze potential clinical and labora-
tory prognostic variables from a surgical and nonsurgical per-
spective by studying cohorts of patients from the registry with 
or without known pathologic staging (i.e., relying on clinical 
tumor, node, metastasis [TNM]) to develop prognostic models.
MATERIALS AND METHODS
Population
From January 4, 1995, to August 18, 2009, a total of 
3101 patients met the screening criteria for having been diag-
nosed with MPM after 1995 and were available for follow-up. 
Of these 3101 patients, 2316 were staged either by patho-
logical findings (pTNM, n = 1976) or by clinical findings 
(cTNM, n = 1265). Of these 2316 cases with the best possible 
TNM staging, 2141 had complete data on age, sex histology, 
and type of surgical procedure, and are cases that form the 
“CORE” model of predictive factors.
Definitions for Supplementary 
Prognostic Variables
The CORE variable demographics for the 2141 sub-
jects are detailed in Table 1. Additional potential prognostic 
clinical variables for MPM that were available in the data-
base included the use of chemotherapy or radiotherapy at any 
time (adjuvant therapy), smoking history, history of asbes-
tos exposure, history of weight loss (defined as greater than 
5% versus lesser than 5% in the previous 6 months), Eastern 
Cooperative Oncology Group (ECOG) PS, chest pain, and 
dyspnea. Smokers included current and former smokers, and 
ECOG PS ranged from 0 to 3 in the full database but was 
limited to 0 to 1 in the 2141 patients included in the analysis. 
For this surgical cohort of patients, 72.2% of patients having 
either a potentially curative (extrapleural pneumonectomy, 
pleurectomy decortication, or other) or a palliative surgical 
procedure (surgical exploration, pleurectomy, or pleurodesis) 
received adjuvant therapy. Laboratory parameters that were 
also analyzed included, hemoglobin, white blood cell count, 
and platelet count. Table 2 documents the number of subjects 
with clinical and laboratory data for these variables. Missing 
data for the 2141 patients ranged from 9.7% (use of adjuvant 
therapy) to 84.4% (history of weight loss).
Statistical Analysis
Survival was measured from date of pathologic diag-
nosis to the date of last contact (at which time they were 
censored) or death attributable to any cause. Median survival 
was estimated using the Kaplan–Meier regression method. 
Prognostic groups were assessed by Cox regression analysis 
of survival, using the SAS system for Windows version 9.2 
(SAS Institute Inc., Cary, NC) PHREG method. Significance 
values from pair-wise comparisons reflect the Wald test; those 
from joint model effects (e.g., comparing the full model to the 
null model) reflect the likelihood ratio test. All covariates in 
regression analyses were modeled categorically using indica-
tor variables, and the threshold for statistical significance was 
set at a p value of 0.05. Age was classified into three catego-
ries, with cutpoints at 50 and 65 years. Covariates that met the 
criteria for statistical significance by univariate analysis were 
further evaluated for inclusion in multivariable regression 
models, using a stepwise algorithm with backward selection.
RESULTS
CORE Model for Survival
Table 3 shows the hazard ratios and p values for compar-
isons based on a Cox regression model of the CORE survival 
model as of March 2013 for all 2141 patients without miss-
ing data. All comparisons shown in the table are significant, 
except stage II versus stage I and the oldest versus the middle 
age groups (not shown). This model can be further consoli-
dated into two categories for age (≥50 years versus younger).
Cox Regression Models: 
Pathological Staging Included
Table 4 shows the results of the Cox regression models 
including each proposed covariate in a univariate model and 
each proposed covariate in addition to the covariates of best 
TABLE 1.  CORE Variable Demographics (n = 2141)
Number Percentage
Stage
  I 242 11.3
  II 452 21.1
  III 1057 49.4
  IV 390 18.2
Age
  <50 324 15.1
  50 to <65 1064 49.7
  65 or older 753 35.2
Sex
  Female 419 19.6
  Male 1722 80.4
Histology
  Epithelioid 1544 72.1
  Nonepithelioid 597 27.9
Surgical procedure
Palliative 671 31.3
EPP 1173 54.8
PD 297 13.9
EPP, extrapleural pneumonectomy; PD, pleurectomy/decortication.
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stage (pathological), histology, sex, age, and type of surgery 
(palliative versus EPP/pleurectomy/decortication). Only the 
covariates that were independently statistically significant in 
addition to the CORE model parameters were included in the 
stepwise Cox regression algorithm. These covariates included 
adjuvant therapy, asbestos exposure, weight loss, chest pain, 
hemoglobin, platelets, and white blood cell count (WBC) 
(Figures 1 and 2). Lack of adjuvant therapy, along with the 
presence of asbestos exposure, weight loss, and chest pain, as 
well as low hemoglobin, high platelet count, and high white 
blood count, was found to be associated with a worse progno-
sis independent of the CORE variables.
Stepwise Cox Regression modeling with backwards 
selection was performed on a number of models, all of which 
included combining the CORE model with combinations of the 
supplementary variables with and without laboratory data. In 
TABLE 2.  Supplementary Variables Used for Modeling 
Survival
Number
Clinical parameters 2141 100.0%
  Adjuvant therapy
   Surgery alone 388 18.1%
   Surgery ± chemo or RT 1546 72.2%
   No data 207 9.7%
  Smoking history
   Nonsmoker 350 16.3%
   Smoker 452 21.1%
   No data 1339 62.5%
History of asbestos exposure
   No 463 21.6%
   Yes/probable exposure 1259 58.8%
   No data 419 19.6%
  History of weight loss
   No 254 11.9%
   Weight loss 79 3.7%
   No data 1808 84.4%
  ECOG PS
   PS 0 283 13.2%
   PS 1 441 20.6%
   No data 1417 66.2%
  Chest pain
   No 593 27.7%
   Chest pain 490 22.9%
   No data 1058 49.4%
  Dyspnea
   No 469 21.9%
   Dyspnea 751 35.1%
   No data 921 43.0%
Laboratory parameters
  Hemoglobin, g/dl
   Total 2141 100.0%
   No data 953 44.5%
   Hemoglobin <14.6 (low) 954 44.6%
   Hemoglobin ≤14.6 (high) 234 10.9%
  White blood cell count, ×103/μl
   Total 2141 100.0%
   No data 1081 50.5%
   WBC ≥15.5 (high) 30 1.4%
   WBC <15.5 (low) 1030 48.1%
  Platelet count, ×103/μl
   Total 2141 100.0%
   No data 676 31.6%
   PLT ≤400 (high) 364 17.0%
   PLT <400 (low) 1101 51.4%
RT, radiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance 
status; WBC, white blood cell count; PLT, platelet count.
TABLE 3.  Analysis of Maximum Likelihood Estimates (n = 2141)
Hazard Ratio p Value
Stage
  II vs. I 1.17 0.0953
  III vs. I 1.48 <0.0001
  IV vs. I 1.86 <0.0001
Histology
Other histology vs. epithelial 1.67 <0.0001
Sex
  Male vs. female 1.27 0.0002
Age
  Age 50–64 vs. <50 1.26 0.0022
  Age 65+ vs. <50 1.34 0.0002
Treatment
Palliative vs. curative intent 1.70 <0.0001
TABLE 4.  Initial Cox Regression Modeling of Supplementary 
Factors
Covariate
Univariate 
Model
Added to  
CORE Model
N HR p Value HR p Value
No adjuvant Trt  
(no vs. yes)
1934 1.712 <0.0001 1.551 <0.0001
Smoking history  
(yes vs. no)
802 1.173 0.0546 1.147 0.113
Asbestos exposure 
(yes/prob vs. no)
1722 1.211 0.002 1.151 0.0344
Weight loss (yes vs. no) 333 1.69 0.0002 1.581 0.0016
ECOG PS (1+ vs. 0) 724 1.288 0.0046 0.935 0.2731
Chest pain (yes vs. no) 1083 1.314 <0.0001 1.306 0.0001
Dyspnea (yes vs. no) 1220 0.981 0.7737 0.96 0.5445
Serum LDH 
(continuous)
474 1 0.5376 1 0.3532
Hemoglobin  
(<14.6 vs. not)
1188 1.297 0.0022 1.37 0.0003
Platelets (≥400 vs. not) 1465 1.602 <0.0001 1.767 <0.0001
WBC (≥15.5 vs. not) 1060 1.71 0.0062 1.869 0.0016
Trt, treatment; Prob, probably; ECOG PS, Eastern Cooperative Oncology Group 
performance status; LDH, lactate dehydrogenase; HR, hazard ratio; WBC, white blood 
cell count.
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FIGURE 1.  Kaplan–Meyer survival curves for clinical parameters detailed in Table 4. IASLC, International Association for the 
Study of Lung Cancer; PS, performance status.
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the initial model, all of the parameters were included, and, after 
this model fit, the covariate with the least significance for pre-
dicting outcomes was removed, and this was continued until all 
the remaining covariates in the model were significant at the 
0.05 level. As seen in Table 5, a number of starting models were 
included, which varied in patient numbers from 268 to 1027.
Because the starting model must have all of the covariates, 
including the CORE variables, only 268 of the 2141 patients 
could be evaluated in this way (set 1 plus labs/set 4: only two 
North American data sets included weight loss). Table 6 reveals 
that the final model included best stage, histology, sex, type of 
surgery, adjuvant treatment, weight loss, and WBC.
The most robust model (but compromised because of 
the exclusion of cases with missing weight loss or asbestos 
exposure data) for 550 patients was set 5 (set 3 plus labs), 
which included an evaluation of best stage, histology, sex, age, 
type of surgery, adjuvant treatment, chest pain, WBC, hemo-
globin, and platelets (Table 7).
Cox Regression Models: Clinical Staging
When clinical stage (available in 1265 patients) was 
substituted in the CORE variables instead of pathologic stag-
ing as the “best stage,” a final model of 627 patients was 
similar to that with pathologic staging with the exception 
that hemoglobin level was also an independent prognostic 
variable (Table 8).
Cox Modeling in the Absence of 
Staging: Presentation Model
To simulate the situation of a potential surgical patient 
presenting only with a diagnosis of mesothelioma before 
any staging procedure to evaluate the patient for surgery, the 
CORE model was adjusted to include only age, histology, and 
sex. In this case, the impact of adjuvant therapy, type of opera-
tion, or staging would be unknown. Of the 2749 individuals 
with CORE variables of histology, sex, and age, 906 individu-
als also had laboratory data. The univariate model (presenta-
tion model) added to the modified CORE model reveals that 
weight loss, chest pain, and the laboratory parameters were 
significant variables (Table 9).
The final model after stepwise backward regression 
(Table 10) reveals that histologic subtype of MPM, sex, age, plate-
let count, and white blood cell count was predictive of outcome.
DISCUSSION
The IASLC Mesothelioma Domain was the first inter-
national effort to improve on the staging of this orphan dis-
ease by establishing an international retrospective registry 
FIGURE 2.  Kaplan–Meyer survival curves for laboratory parameters detailed in Table 4. IASLC, International Association for the 
Study of Lung Cancer; WBC, WBC, white blood cell count; Hgb, hemoglobin; PLT, platelet count.
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examining CORE variables associated with survival after 
either palliative or after potentially curative surgery. CORE 
variables that were associated in multivariate analyses to be 
prognostically important included best stage, age, sex, histol-
ogy (epithelioid or not), and the type of surgical procedure 
(palliative versus EPP/progressive disease). The 2141 patients 
in the present registry represent the largest such collection of 
surgically treated patients with mesothelioma, in whom all of 
these CORE variables were recorded.4
When the registry was first developed, the regis-
try designers were influenced by the Cancer and Leukemia 
Group B and the EORTC prognostic indices that were the first 
to attempt to define additional factors, which included PS, 
symptoms, and selected laboratory parameters. The EORTC 
analysis eventually included not only overall survival but also 
progression-free survival.5 The clinical factors chosen for the 
IASLC Mesothelioma Registry supplementary prognostic 
analyses included the use of chemotherapy at any time (adju-
vant therapy), smoking history, history of asbestos exposure, 
history of weight loss, defined as greater than 5% versus less 
than 5% in the previous 6 months, ECOG PS, chest pain, and 
dyspnea. Laboratory parameters included hemoglobin level, 
platelet count, white blood cell count, and lactate dehydro-
genase level before the attempted surgical procedures. The 
chemotherapy data were standardized neither for the regimen 
used nor for the timing of the therapy, that is, neoadjuvant 
TABLE 6.   Stepwise Regression Modeling for 268 Patients 
with All Variables
Variable Hazard Ratio p Value
Stage II vs. I 1.52 0.2389
III vs. I 2.61 0.0031
IV vs. I 3.60 0.0004
Histology Other histology vs. epithelial 1.74 0.0001
Sex Male vs. female 2.30 <0.0001
Treatment Palliative vs. curative intent 2.66 0.0002
Adjuvants Adjuvant treatment: no vs. yes 1.71 0.0008
Weight loss Yes vs. no 1.48 0.0155
WBC ≥15.5 vs. <15.5 3.77 0.0004
WBC, white blood cell count.
TABLE 5.  Number of Cases with Addition Prognostic Factors Available by Source
Set 1 Set 2 Set 3 Set 4 Set 5
Labs, WBC,  
Hemoglobin, 
Platelets
CORE  
Variables Only
adj trt, Asbestos  
Exposure, Weight 
Loss, Chest Pain
adj trt, Asbestos 
Exposure,  
Chest Pain
adj trt,  
Chest 
Pain Set 1 + Labs Set 3 + Labs
NCI/WSU/NYU (USA) 141 184 156 179 183 137 140
MDACC (USA) 170 173 134 134 167 131 164
EORTC 42 42 0 37 42 0 42
JLHWO (JPN) 0 129 0 124 129 0 0
Ankara (TUR) 0 221 0 0 0 0 0
Padova (ITA) 57 85 0 56 85 0 57
IEO (ITA) 134 135 0 35 46 0 46
Leicester (GBR) 157 177 0 0 0 0 0
Zurich (CHE) 106 128 0 128 128 0 106
Toronto (CAN) 23 82 0 0 0 0 0
Heidelberg (DEU) 0 97 0 0 0 0 0
MSKCC (USA) 0 514 0 125 142 0 0
MesoNat (FRA) 0 10 0 9 9 0 0
Sydney (AUS) 0 67 0 0 0 0 0
Torino (ITA) 0 97 0 95 96 0 0
Total 830 2141 290 922 1027 268 550
NCI, National Cancer Institute; WSU, Wayne State University; NYU, New York University; MDACC, M. D. Anderson Cancer Center; EORTC, European Organisation for Research 
and Treatment of Cancer; JLHWO, Japan Labour, Health, and Welfare Organization Hospitals; IEO, Istituto Europeo di Oncologia; MSKCC, Memorial Sloan Kettering Cancer Center; 
adj, adjuvant; trt, treatment; WBC, white blood cell count.
TABLE 7.  Final Model of Clinical, Pathologic, and 
Laboratory Variables (n = 550)
 Variable Hazard Ratio p Value
Stage Pathologic stage II vs. I 1.48 0.0802
Pathologic stage III vs. I 2.2 0.0002
Pathologic stage IV vs. I 2.49 0.0001
Histology Other histology vs. epithelial 1.8 <0.0001
Sex Male vs. female 1.7 0.0006
Age Age ≥50 vs. younger 1.61 0.012
Treatment Palliative vs. curative intent 1.67 0.0008
Adjuvant  
treatment
No vs. yes 1.7 0.0002
Platelets ≥400 vs. <400 1.5 0.0004
WBC ≥15.5 vs. <15.5 2.39 0.0007
WBC, white blood cell count.
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or postoperative. In fact, whether the patients received preop-
erative or postoperative chemotherapy (or both) could not be 
ascertained from the data because it was collected, and this 
can be construed as a weakness of this registry. Moreover, 193 
patients had radiation along with surgery without chemother-
apy, 608 had chemotherapy along with surgery but no radia-
tion, and 579 surgery patients had both chemotherapy and 
radiotherapy, and any subanalysis of these cohorts for supple-
mental prognostic factors did not have enough common ele-
ments to make insightful conclusions. The extent of missing 
data in this first registry is unfortunate but it is hoped that this 
problem will be minimized in the ongoing prospective registry. 
For the final analysis, only 252 of the 2141 (12%) individuals, 
representing data from four North American Institutions had 
information on all of these supplementary variables in addi-
tion to the CORE variables, and stepwise regression model-
ing revealed that adjuvant therapy use, smoking history, WBC 
level, and weight loss were prognostically relevant. Indeed, the 
parameters that were most problematic included smoking his-
tory, weight loss, and ECOG PS. Because this was a surgical 
series of patients, it can be safely assumed that the majority of 
patients were ECOG 0 or 1, and that PS may not stratify in the 
models because of its relative homogeneity. Other factors such 
as the important symptom of chest wall pain, as well as all 
of the laboratory parameters, were recorded in approximately 
50% of the patients with CORE variables. As such, further 
analyses using as many patients as possible with the remain-
der of the supplementary variables and laboratory values (n = 
550) revealed that adjuvant therapy, WBC count, and platelets 
were prognostic indicators. Obviously one must consider that 
such analyses are compromised by the missing data; however, 
the number of patients in these internationally based, but com-
promised, analyses compares favorably with all of the studies 
to date attempting to prognosticate MPM using clinical and 
laboratory data.
The goal of registries such as this one is to be able to 
find those prognostic factors that have high fidelity and require 
minimal cost/invasion of the patient, and that in some combina-
torial model would potentially change the treatment algorithm 
for a mesothelioma patient. Because this is a surgical based reg-
istry, there are obvious advantages in developing such models, 
including the presence of complete pathologic data from the 
time of the cytoreduction. In real life, however, the decision to 
operate on a patient with mesothelioma relies on factors apart 
or potentially complementary to pathologic stage, which is a 
major portion of the CORE variables in this study. An analysis 
of the cohort of 906 patients, who had parameters that could be 
TABLE 8.   Final Model, Clinical Staging Only (n = 627)
Hazard Ratio p Value
Clinical stage Clinical stage II vs. I 1.43 0.0098
Clinical stage III vs. I 1.35 0.0358
Clinical stage IV vs. I 1.57 0.0506
Histology Other histology vs. epithelial 1.80 <0.0001
Sex Male vs. female 1.72 0.0002
Age Age ≥50 vs. younger 1.51 0.0198
Treatment Palliative vs. curative intent 1.36 0.0286
Adjuvant  
treatment
No vs. yes 1.65 <0.0001
Hemoglobin <14.6 vs. ≥14.6 1.41 0.0051
Platelets ≥400 vs. <400 1.48 0.0003
WBC ≥15.5 vs. <15.5 1.69 0.0373
WBC, white blood cell count.
TABLE 9.  Cox Regression Modeling: Presentation Model
Univariate Model
Added to Modified  
CORE Modela
Covariate N HR p Value HR p Value
Smoking history (yes vs. no) 881 1.173 0.0439 1.142 0.0997
Asbestos exposure (yes/prob vs. no) 1995 1.223 0.0006 1.104 0.1088
Weight loss (yes vs. no) 378 1.840 <0.0001 1.790 <0.0001
ECOG PS (1+ vs. 0) 1015 0.961 0.5651 0.891 0.1005
Chest pain (yes vs. no) 1254 1.263 0.0003 1.295 <0.0001
Dyspnea (yes vs. no) 1436 0.991 0.8874 0.954 0.4470
Serum LDH (continuous) 547 1.000 0.4987 1.000 0.5824
Hemoglobin (<14.6 vs. not) 1299 1.279 0.0022 1.300 0.0012
Platelets (≥400 vs. not) 1585 1.600 <0.0001 1.699 <0.0001
WBC (≥15.5 vs. not) 1142 1.755 0.0029 1.755 0.0029
aAge, histology, and sex.
LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; WBC, white blood cell count.
TABLE 10.  Final Presentation Model without Staging (n = 906)
Variable Hazard Ratio p Value
Histology Other histology vs. epithelial 1.798 <0.0001
Sex Male vs. female 1.535 0.0003
Age <50 vs. older 1.568 0.0011
Platelets <400 vs. ≥400 1.707 <0.0001
WBC <15 vs. ≥15 1.763 0.0059
WBC, white blood cell count.
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assessed noninvasively on presentation, validated the findings 
of many of the previous studies listed in Table 11. The pheno-
type for a poor prognosis was defined as males older than 50 
years old who presented with nonepithelial histotype and ele-
vated platelet and WBC counts.2,3,5–13
The future and use of the MPM registry will depend 
on prospective accumulation of international cases along with 
uniform standardization of important demographic variables. 
For the CORE variables, further subdivision of the type and 
extent of surgical cytoreduction will be accomplished by the 
incorporation of recently published guidelines for their defi-
nition.14 Supplementary prognostic fields must be expanded 
to include more precise quantification of radiographic 
parameters, such as tumor volume and standardization of 
positron emission tomography-computed tomography inter-
pretation15–19 (Table 12). Numerous studies have documented 
a relationship between post-treatment/postsurgical MPM sur-
vival and elevated standard uptake values (SUV); however, 
validation of a specific threshold standardized uptake value or 
standardization of SUV quantitation is lacking.
TABLE 11.  Clinicopathologic Prognostic Studies of MPM
Year Author N Univariate Predictors Multivariate Predictors
2013 Baud 170 Asbestos exposure, age, ASA class III vs. ASA classes I and 
II, nonepithelioid histology, CRP >3 mg/liter, and white cell 
count >12,000/mm3
Nonepithelioid histology, age, CRP, WBC 
>12,000/mm3
2011 Nojiri 314 Demographic and laboratory parameters Age >70, nonepithelial, low PS, high WBC, 
High CRP
2010 Tanrikulu 363 Glucose <40,CRP >50 ↓ survival KPS, serum LDH, presence of pleural effusion, 
pleural thickening >1 cm, and PLT >420 k
2010 Richards 354 Stratification of T and N status, epithelial only N2b vs. N2a nodal status with different hazard 
ratio
2009 Francart 523 PS >0, stage IV, nonepithelial ↓ PFS Age, histotype, stage, PS, hgb, WBC
2009 Yan 456 Young age, pleural effusion, epithelial, EPP, PET scan, adjuvant 
therapy ↑ survival
Epithelial and EPP: ↑ survival
2007 Flores 945 Histology, sex, smoking, asbestos exposure, laterality, surgical 
resection by extrapleural pneumonectomy or pleurectomy/ 
decortication, American Joint Committee on Cancer stage, 
and symptoms
Surgical resection, nonsmokers, female, no pain, 
epithelial, left side: ↑ survival
2005 Steele 145 EORTC prognostic index: PS, nonepithelial, male, low hgb, high 
platelet count, high WBC, high LDH ↓ survival
PS, WBC, hgb, uncertain diagnosis, 
sarcomatoid: ↓ survival
2004 Neumann 155 Epithelial, young age, female sex ↑ survival Epithelial, young age, female sex: ↑survival
2000 Edwards 142 Male sex, older age, weight loss, chest pain, poor PS, low hgb, 
leukocytosis, thrombocytosis, and nonepithelial cell type ↓ 
survival
Cell type, hgb, white cell count, PS, and sex
1998 Herndon 337 CALGB prognostic index: PS, chest pain, dyspnea, PLT 
>400,000/μl, weight loss, LDH level >500 IU/liter, pleural 
involvement, low hgb level, high WBC count, and increasing 
age older than 75 years
Pleural involvement, LDH >500 IU/liter, poor 
PS, chest pain, PLT >400,000, nonepithelial 
histology, and increasing age older than 75 
years
PET, positron emission tomography; PS, performance status; PFS, progression-free survival; LDH, lactate dehydrogenase; hgb, hemoglobin; PLT, platelet count; WBC, white blood 
cell count; CRP, C reactive protein; CALGB, Cancer and Leukemia Group B; MPM, malignant pleural mesothelioma; EORTC, European Organisation for Research and Treatment of 
Cancer; KPS, Karnovsky performance status; EPP, extrapleural neumonectomy; ASA, American Society of Anesthesiologists.
Table was modified from the study by Pass.25
TABLE 12.  Radiographic Prognostic Studies
Marker Year Author N Univariate Predictors Multivariate Predictors
PET-CT 2013 Abakay 177 Male sex, nonepithelial, KPS <60, stage III to IV, hgb <12.3 g/dl, 
serum ALP >79 U/liter, presence of pleural thickening >1 cm, 
BSC treatment regimen, SUVmax >5
Male sex, KPS <60, BSC, stage III to 
IV, SUVmax >5
CT volume 2012 Gill 88 Tumor volume predicts survival after EPP Tumor volume, hgb, adjuvant therapy
PET-CT 2011 Sharif 1108 SUV >10 associated with decreased survival in best-evidence 
review of 15 articles
NA
PET-CT volume 2010 Lee 13 High metabolic tumor volume decreased survival Metabolic tumor volume
Quantitative FDG 2010 Nowak 89 High total glycolytic volume decreased survival, histology, weight 
loss, CT stage, EORTC prognostic score
Total glycolytic volume and weight loss 
for sarcomatoid histology
PET, positron emission tomograpy; CT, computerized tomography; SUV, standardized uptake value; hgb, hemoglobin; KPS, Karnovsky performance status; BSC, best supportive care; 
ALP, alkaline phosphatase; EORTC, European Organisation for Research and Treatment of Cancer; FDG, fluoroxy-deoxyglucose; EPP, extrapleural pneumonectomy; NA, not available.
Table was modified from the study by Pass.25
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Finally, a number of tissue-based and blood-based 
genomic, epigenetic, and proteomic markers have been pub-
lished either as single entities or as part of a profile for the 
prognostication of MPM.20–24 The majority of these have not 
been validated either in independent cohorts or in blinded 
analyses. The challenge for the registry is whether such mark-
ers can be added as fields. At the least, however, if the prospec-
tive registry is maintained, and participating institutions have 
ongoing tissue and blood procurement protocols for archiving 
of samples, the registry will represent a valuable coordinating 
entity for such validations.
ACKNOWLEDGMENTS
The Mesothelioma Applied Research Foundation and 
the International Association for the Study of Lung Cancer 
provided funding to support the International Mesothelioma 
Staging Project. The sponsors had no input in the committee’s 
analysis of the data or in the committee’s suggestions for revi-
sions to the staging system.
REFERENCES
 1. Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction 
in the treatment of malignant pleural mesothelioma: meeting summary of 
the International Mesothelioma Interest Group Congress, September 11–
14, 2012, Boston, Mass. J Thorac Cardiovasc Surg 2013;145:909–1010.
 2. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the 
EORTC prognostic model for malignant pleural mesothelioma based on 
three consecutive phase II trials. J Clin Oncol 2005;23:184–189.
 3. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne 
KJ. Prognostic factors for malignant mesothelioma in 142 patients: 
validation of CALGB and EORTC prognostic scoring systems. Thorax 
2000;55:731–735.
 4. Rusch VW, Giroux D, Kennedy C, et al; IASLC Staging Committee. 
Initial analysis of the International Association for the Study of Lung 
Cancer mesothelioma database. J Thorac Oncol 2012;7:1631–1639.
 5. Francart J, Vaes E, Henrard S, et al. A prognostic index for progression-
free survival in malignant mesothelioma with application to the design 
of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 
2009;45:2304–2311.
 6. Baud M, Strano S, Dechartres A, et al. Outcome and prognostic factors 
of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J 
Thorac Cardiovasc Surg 2013;145:1305–1311.
 7. Nojiri S, Gemba K, Aoe K, et al. Survival and prognostic factors in malig-
nant pleural mesothelioma: a retrospective study of 314 patients in the 
west part of Japan. Jpn J Clin Oncol 2011;41:32–39.
 8. Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radiographic and 
laboratory evaluation of prognostic factors in 363 patients with malignant 
pleural mesothelioma. Respiration 2010;80:480–487.
 9. Richards WG, Godleski JJ, Yeap BY, et al. Proposed adjustments to 
pathologic staging of epithelial malignant pleural mesothelioma based on 
analysis of 354 cases. Cancer 2010;116:1510–1517.
 10. Yan TD, Boyer M, Tin MM, et al. Prognostic features of long-term survi-
vors after surgical management of malignant pleural mesothelioma. Ann 
Thorac Surg 2009;87:1552–1556.
 11. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the 
treatment of malignant pleural mesothelioma at a large tertiary referral 
center. J Thorac Oncol 2007;2:957–965.
 12. Neumann V, Rütten A, Scharmach M, Müller KM, Fischer M. Factors 
influencing long-term survival in mesothelioma patients—results of 
the German mesothelioma register. Int Arch Occup Environ Health 
2004;77:191–199.
 13. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang 
NJ. Factors predictive of survival among 337 patients with mesothelioma 
treated between 1984 and 1994 by the Cancer and Leukemia Group B. 
Chest 1998;113:723–731.
 14. Rice D, Rusch V, Pass H, et al; International Association for the Study 
of Lung Cancer International Staging Committee and the International 
Mesothelioma Interest Group. Recommendations for uniform definitions 
of surgical techniques for malignant pleural mesothelioma: a consensus 
report of the International Association for the Study of Lung Cancer 
International Staging Committee and the International Mesothelioma 
Interest Group. J Thorac Oncol 2011;6:1304–1312.
 15. Abakay A, Komek H, Abakay O, et al. Relationship between 18 FDG 
PET-CT findings and the survival of 177 patients with malignant pleural 
mesothelioma. Eur Rev Med Pharmacol Sci 2013;17:1233–1241.
 16. Gill RR, Richards WG, Yeap BY, et al. Epithelial malignant pleural 
mesothelioma after extrapleural pneumonectomy: stratification of sur-
vival with CT-derived tumor volume. AJR Am J Roentgenol 2012;198: 
359–363.
 17. Sharif S, Zahid I, Routledge T, Scarci M. Does positron emission tomog-
raphy offer prognostic information in malignant pleural mesothelioma? 
Interact Cardiovasc Thorac Surg 2011;12:806–811.
 18. Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18F-
FDG PET/CT in malignant pleural mesothelioma: prediction of 
therapeutic response and prognostic implications. Ann Surg Oncol 
2010;17:2787–2794.
 19. Nowak AK, Francis RJ, Phillips MJ, et al. A novel prognostic model for 
malignant mesothelioma incorporating quantitative FDG-PET imaging 
with clinical parameters. Clin Cancer Res 2010;16:2409–2417.
 20. Gordon GJ, Dong L, Yeap BY, et al. Four-gene expression ratio test for 
survival in patients undergoing surgery for mesothelioma. J Natl Cancer 
Inst 2009;101:678–686.
 21. Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the 
prognosis of malignant pleural mesothelioma. Cancer Res 2010;70: 
1916–1924.
 22. Kao SC, Vardy J, Chatfield M, et al. Validation of prognostic factors in 
malignant pleural mesothelioma: a retrospective analysis of data from 
patients seeking compensation from the New South Wales Dust Diseases 
Board. Clin Lung Cancer 2013;14:70–77.
 23. Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression 
and high neutrophil-to-lymphocyte ratio are poor prognostic factors in 
patients with malignant mesothelioma undergoing extrapleural pneumo-
nectomy. J Thorac Oncol 2011;6:1923–1929.
 24. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte 
ratio is an indicator of poor prognosis in malignant mesothelioma patients 
undergoing systemic therapy. Clin Cancer Res 2010;16:5805–5813.
 25. Pass HI. Biomarkers and prognostic factors for mesothelioma. Ann 
Cardiothorac Surg 2012;1:449–456.
